Definium Therapeutics (DFTX) Stock May Trade At A Premium Despite Phase 3 DT120 Results

Definium Therapeutics has ridden a powerful three year run, and that surge now puts a spotlight on a simple question for investors who care about balance sheets. Is the current share price still grounded in what the business is worth on its books, or has sentiment pulled it away from its underlying equity value? Over the past three years, Definium Therapeutics has delivered a return of roughly 8.9x, which raises the stakes for whether the stock price still lines up with the value recorded on...